Methylene Blue for the Prevention of Hypotension During Hemodialysis

• Status: Not yet recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Hypotension is a common complication of intermittent renal replacement therapy. Methylene blue, an inhibitor of nitric oxide synthesis, has been suggested to improve hemodynamics during renal replacement therapy in ambulatory patients, but evidence is lacking for critically ill patients.

This trial will assess whether methylene blue can improve hemodynamics and blood pressure for patients with shock requiring renal replacement therapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Federal University of São Paulo
• Treatments: Methylene Blue

Criteria

Inclusion Criteria:

1. Patient or legal representative accepted trial enrollment

2. Age above 18 years

3. Chronic or acute kidney injury in need for renal replacement therapy

4. Blood pressure lower than 100 mmHg or in use of any vasopressor

Exclusion Criteria:

1. Pregnancy

2. Death considered imminent in the next 24 hours

3. Patients not on full code status

4. Hypertensive patients where dialysis was indicated to remove fluids

5. Known allergy to methylene blue

6. Known glucose-6-phosphate deficiency

7. Previously enrolled in the trial

8. Acute coronary Syndrome

9. Domiciliary nitrate use